DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: DELZICOL

Summary for Tradename: DELZICOL

Patents:3
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 DELZICOL

Pharmacology for Tradename: DELZICOL

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate

Clinical Trials for: DELZICOL

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers
Status: Completed Condition: Healthy

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
Status: Completed Condition: Colitis, Ulcerative; Recurrence

Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis
Status: Recruiting Condition: Ulcerative Colitis

The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Status: Recruiting Condition: Irritable Bowel Syndrome

Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Status: Completed Condition: Healthy

Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.
Status: Completed Condition: Ulcerative Colitis

The Colitis Once Daily Asacol Study
Status: Completed Condition: Ulcerative Colitis

Predicting Response to Standardized Pediatric Colitis Therapy
Status: Recruiting Condition: Ulcerative Colitis

Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Status: Completed Condition: Healthy

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
Status: Completed Condition: Irritable Bowel Syndrome

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Warner Chilcott Llc
DELZICOL
mesalamine
CAPSULE, DELAYED RELEASE;ORAL204412Feb 1, 2013RXYes5,541,170<disabled>Y<disabled>
Warner Chilcott Llc
DELZICOL
mesalamine
CAPSULE, DELAYED RELEASE;ORAL204412Feb 1, 2013RXYes5,541,171<disabled>Y<disabled>
Warner Chilcott Llc
DELZICOL
mesalamine
CAPSULE, DELAYED RELEASE;ORAL204412Feb 1, 2013RXYes6,649,180<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc